- Home
- NE vs PTGX Comparison
NE vs PTGX Comparison
Compare NE & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NE
- PTGX
- Stock Information
- Founded
- NE 1985
- PTGX 2006
- Country
- NE United States
- PTGX United States
- Employees
- NE N/A
- PTGX N/A
- Industry
- NE Other Specialty Stores
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- NE Consumer Discretionary
- PTGX Health Care
- Exchange
- NE Nasdaq
- PTGX Nasdaq
- Market Cap
- NE 3.5B
- PTGX 3.3B
- IPO Year
- NE N/A
- PTGX 2016
- Fundamental
- Price
- NE $28.34
- PTGX $55.15
- Analyst Decision
- NE Buy
- PTGX Strong Buy
- Analyst Count
- NE 8
- PTGX 9
- Target Price
- NE $33.29
- PTGX $67.11
- AVG Volume (30 Days)
- NE 2.1M
- PTGX 790.5K
- Earning Date
- NE 08-05-2025
- PTGX 08-05-2025
- Dividend Yield
- NE 7.06%
- PTGX N/A
- EPS Growth
- NE N/A
- PTGX N/A
- EPS
- NE 2.96
- PTGX 0.86
- Revenue
- NE $3,138,770,000.00
- PTGX $207,801,000.00
- Revenue This Year
- NE $15.49
- PTGX N/A
- Revenue Next Year
- NE $1.81
- PTGX $53.09
- P/E Ratio
- NE $9.57
- PTGX $63.94
- Revenue Growth
- NE 25.61
- PTGX N/A
- 52 Week Low
- NE $17.40
- PTGX $32.50
- 52 Week High
- NE $48.40
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- NE 53.44
- PTGX 56.72
- Support Level
- NE $26.54
- PTGX $51.55
- Resistance Level
- NE $29.29
- PTGX $57.73
- Average True Range (ATR)
- NE 1.03
- PTGX 1.74
- MACD
- NE -0.10
- PTGX -0.07
- Stochastic Oscillator
- NE 38.44
- PTGX 69.13
About NE Noble Corporation plc A
Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units. The company focuses on a high-specification fleet of floating and jackup rigs and the deployment of its drilling rigs in oil and gas basins around the world.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.